Mike Kratky
Stock Analyst at Leerink Partners
(3.34)
# 851
Out of 4,814 analysts
27
Total ratings
42.11%
Success rate
31.06%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBNX Beta Bionics | Initiates: Outperform | $28 | $11.18 | +150.45% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $7.51 | +59.79% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $68.61 | +26.80% | 2 | Oct 25, 2024 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $167 → $197 | $150.00 | +31.33% | 2 | Sep 10, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $277.77 | -5.32% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $16.86 | +166.98% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $10.80 | +103.70% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $246.95 | -25.49% | 1 | Oct 16, 2023 | |
| VCEL Vericel | Initiates: Outperform | $42 | $41.19 | +1.98% | 1 | Oct 16, 2023 | |
| ISRG Intuitive Surgical | Initiates: Outperform | $342 | $482.40 | -29.10% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $71.56 | +4.81% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $53.04 | -30.24% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $15.56 | -42.16% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $2.43 | +1,957.61% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.46 | +2,982.19% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $301.73 | +4.40% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $26.00 | +19.23% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $15.15 | -7.56% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $13.10 | +205.34% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $48 | $0.79 | +5,977.49% | 1 | Aug 11, 2022 |
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $11.18
Upside: +150.45%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $7.51
Upside: +59.79%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $68.61
Upside: +26.80%
Inspire Medical Systems
Sep 10, 2024
Maintains: Market Perform
Price Target: $167 → $197
Current: $150.00
Upside: +31.33%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $277.77
Upside: -5.32%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $16.86
Upside: +166.98%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $10.80
Upside: +103.70%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $246.95
Upside: -25.49%
Vericel
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $41.19
Upside: +1.98%
Intuitive Surgical
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $482.40
Upside: -29.10%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $71.56
Upside: +4.81%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $53.04
Upside: -30.24%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $15.56
Upside: -42.16%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $2.43
Upside: +1,957.61%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.46
Upside: +2,982.19%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $301.73
Upside: +4.40%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $26.00
Upside: +19.23%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $15.15
Upside: -7.56%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $13.10
Upside: +205.34%
Aug 11, 2022
Maintains: Outperform
Price Target: $49 → $48
Current: $0.79
Upside: +5,977.49%